Course Information
The purpose of this program is to provide urologists with practical knowledge that will allow them to respond effectively to the needs to patients with Castration Resistant Prostate Cancer.
Acknowledgements
The American Urological Association would like to thank the following companies for providing educational grants in support of the Castration-Resistant Prostate Cancer: Care through Continuum Webcast:
AbbVie
Medivation
AUA ensures that all educational activities are developed and implemented independent of the control and/or influence of any commercial interests (ACCME: SCS1)
Learning Objectives:
Module 1: AUA Guideline and Amendments
After viewing this module, participants should be able to complete the following:
• Demonstrate an enhanced understanding of the disease state of CRPC utilizing clinical factors, including the presence or absence of metastases, the degree and severity of symptoms, the patient’s performance status, and implications of prior use of docetaxel chemotherapy
• Analyze the evidence on the treatment of castration-resistant prostate cancer as outlined in the AUA guideline and subsequent amendments
• Improve diagnostic and therapeutic decision making processes by illustrating the application of these guideline in urologic practice
• Acquire in-depth knowledge on the process by which evidence is used to develop scientifically rigorous, yet actionable, guidelines
Module 2: Pain Management
After viewing this module, participants should be able to complete the following:
• Understand the need for a multidisciplinary approach to the care of CRPC patients in regards to the management of pain
• Identify disease- and treatment-related causes of pain commonly seen in the CRPC patient
• Improve the pain management process by understanding preventative measures and management strategies used in the treatment of men diagnosed with CRPC
Module 3: Sequencing of Agents
After viewing this module, participants should be able to complete the following:
• Identify the FDA-approved agents for use in men with CRPC as well as the pivotal trials that resulted in their indications
• Analyze where the FDA approved agents apply in the management of CRPC
• Understand the knowledge gaps present in current CRPC research and identify areas of interest to better aid in the sequencing of treatment agents
Faculty
William Lowrance, MD, MPH (AUA CRPC Clinical Guideline Amendment Chair)
Assistant Professor
University of Utah School of Medicine
Michael Cookson MD, MMHC (AUA CRPC Clinical Guideline Chair)
Chairman Dept of Urology and Professor
University of Oklahoma College of Medicine
Bruce Roth, MD (Panel Member, AUA CRPC Clinical Guideline and Amendment)
Professor
Washington University School of Medicine in St. Louis
Natalie Moryl, MD (Pain Management)
Internist
Memorial Sloan Kettering Cancer Center
Method of Participation
To claim CME credit/hours of participation for each webcast, the learner must complete to pre-test view the webcast, complete the posttest, passing with 80% accuracy and submit the evaluation.
Estimated time to complete this activity: 1.0 hour
Release Date: December, 2015
Expiration Date: December, 2016
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
Michael Cookson, MD: Bayer: Meeting Participant or Lecturer, Scientific Study or Trial
William Lowrance, MD: Myraid Genetics: Scientific Study or Trial; Genome Dx: Scientific Study or Trial; Argos: Scientific Study or Trial
Natalie Moryl, MD: Nothing to disclose
Bruce Roth, MD: Oncogenix: Scientific Study or Trial; Argos Scientific Study or Trial
Planner Disclosures:
Education Council
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Released date: December, 2015
Expiration date: December, 2016
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
To claim CME credit/hours of participation for each webcast, the learner must complete to pre-test view the webcast, complete the posttest, passing with 80% accuracy and submit the evaluation.
Estimated time to complete this activity: 1.0 hour
Release Date: December, 2015
Expiration Date: December, 2016
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Michael Cookson, MD: Bayer: Meeting Participant or Lecturer, Scientific Study or Trial
William Lowrance, MD: Myraid Genetics: Scientific Study or Trial; Genome Dx: Scientific Study or Trial; Argos: Scientific Study or Trial
Natalie Moryl, MD: Nothing to disclose
Bruce Roth, MD: Oncogenix: Scientific Study or Trial; Argos Scientific Study or Trial
Planner Disclosures:
Education Council
Name | Company | Role | Financial |
Timothy Charles Brand ,M.D. | Nothing to Disclose | ||
Peter Robert Carroll, MD, MPH | NIH | Scientific Study or Trial | Yes |
Department of Defense | Scientific Study or Trial | Yes | |
Myriad Genetics | Scientific Study or Trial | No | |
AUA Update | Leadership Position | Yes | |
Genomic Health | Scientific Study or Trial | No | |
Sam S. Chang, MD | Astellas | Consultant or Advisor | Yes |
NIH | Scientific Study or Trial | Yes | |
Cold Genesys, Inc | Scientific Study or Trial | Yes | |
GLG | Consultant or Advisor | Yes | |
Bayer | Consultant or Advisor | Yes | |
Pat Fox Fulgham, MD | Urology Clinics of North Texas | Investment Interest | Yes |
Matthew Thomas Gettman MD | Nothing to Disclose | ||
Inderbir Singh Gill ,M.D., M.Ch. | Hansen Medical | Investment Interest | Yes |
EDAP | Consultant or Advisor | Yes | |
EDAP | Consultant or Advisor | Yes | |
Mimic | Consultant or Advisor | Yes | |
Christina Giffin (AUA Staff) | Nothing to Disclose | ||
Misop Han, MD | Nothing to Disclose | ||
David Alan Hatch ,M.D. | Pfizer | Scientific Study or Trial | Yes |
Douglas A. Husmann MD | Nothing to Disclose | ||
Mark L. Jordan, M.D., F.A.C.S | Nothing to Disclose | ||
Louis Koncz ,PA-C | American Medical Systems | Meeting Participant or Lecturer | Yes |
Tracey Lynn Krupski, MD | Nothing to Disclose | ||
Cheryl Taylore Lee, MD | Endo Pharmaceuticals | Scientific Study or Trial | Yes |
Yair Lotan ,M.D. | Abbott | Scientific Study or Trial | No |
Danone | Consultant or Advisor, Scientific Study or Trial | Yes | |
Cepheid | Scientific Study or Trial | No | |
Pacific Edge | Scientific Study or Trial | No | |
FKD | Scientific Study or Trial | No | |
MDxHealth | Consultant or Advisor | Yes | |
Biocancell | Scientific Study or Trial | No | |
Genomic Health | Scientific Study or Trial | No | |
GenomeDx Biosciences Inc | Scientific Study or Trial | No | |
Photocure | Scientific Study or Trial | No | |
Jill A. Macoska PhD | Nothing to Disclose | ||
Manoj Monga, MD, FACS | Fortec | Other | Yes |
Endourology Society | Leadership Position | No | |
Practical Reviews in Urology | Health Publishing | Yes | |
Victor William Nitti, MD (AUA Staff) |
Astellas | Health Publishing, Scientific Study or Trial | No |
Allergan | Health Publishing, Scientific Study or Trial | No | |
Serenity Pharmeuticals | Investment Interest | Yes | |
Cook Myosite | Scientific Study or Trial | No | |
Gail S. Prins PhD | Nothing to Disclose | ||
Lee Richstone, MD | Nothing to Disclose | ||
Karl-Dietrich Sievert ,M.D., Ph.D. | AMS | Meeting Participant or Lecturer | Yes |
Karl Storz | Meeting Participant or Lecturer | Yes | |
Medtronics | Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
Allergen | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
Neotract | Meeting Participant or Lecturer | Yes | |
Joseph A. Smith Jr.,M.D. | Nothing to Disclose | ||
Sean Patrick Stroup | Intuitive Surgical | Meeting Participant or Lecturer | Yes |
NeoTract | Meeting Participant or Lecturer | Yes | |
Edouard John Trabulsi, M.D. | Nothing to Disclose |
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Released date: December, 2015
Expiration date: December, 2016
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.